Back to today’s briefing

Story perspectives

Regulators Target Hims & Hers Over Obesity Drug Copycat

2/20/2026

33 5 Full Breakdown

Summary

Story summary

U.S. regulators deem Hims & Hers Health's compounded oral semaglutide an illegal copycat, prompting a Novo Nordisk lawsuit.
Despite rapid sales growth, analysts expect Hims to decline as competition and regulatory scrutiny rise.
The obesity drug market could reach $100 billion by 2030, with pills capturing a large share.
Experts warn Hims' liposomal oral-delivery technology may create safety risks and manufacturing challenges.

1 of 1

Story summary

U.S. regulators deem Hims & Hers Health's compounded oral semaglutide an illegal copycat, prompting a Novo Nordisk lawsuit.
Despite rapid sales growth, analysts expect Hims to decline as competition and regulatory scrutiny rise.
The obesity drug market could reach $100 billion by 2030, with pills capturing a large share.
Experts warn Hims' liposomal oral-delivery technology may create safety risks and manufacturing challenges.